Health
FDA approves Lisraya for dermatomyositis in adults
The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets as the first oral treatment for dermatomyositis in adults.
Story Brief
Food and Drug Administration has approved Lisraya (brepocitinib) tablets as the first oral treatment for dermatomyositis in adults. The approval was based on results from a phase 3 trial in which 241 adults with dermatomyositis were randomly assigned to receive Lisraya (30 mg once daily or 15 mg once daily) or a placebo.
Read full article on Medical XpressAI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Rare antibodies with potential to combat alpha-gal syndrome identifiedContinue reading
- One flash of red light could check health of bioprinted tissue and implantsContinue reading
- Online mental health care is here to stay: Here's how to navigate your options and find the right clinicianContinue reading
- Five ways the human body can sync up with other peopleContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow